Fortacin set for centralised OTC switch in Europe
24 July 2020
Recordati’s Fortacin (lidocaine and prilocaine) is set to become the fifth medicine to gain non-prescription status through the European Union’s centralised authorisation procedure.
Industry News - Tag: Recordati
You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
Industry in brief | Recordati, Adare, Phynova
11 May 2020
Recordati has released financial results, Adare Pharmaceuticals has acquired Orbis Biosciences, and Phynova is raising EUR10 million (USD11 million).
Two centralised OTC switch applications are ongoing
Premium
30 March 2020
Two applications to switch medicines from prescription to non-prescription status through the European Union’s centralised authorisation procedure are still in progress.
Europe to consider two centralised OTC switches
Premium
20 March 2020
Two applications to switch medicines from prescription to non-prescription status through the European Union’s centralised authorisation procedure are set to be discussed by the Committee for Medicinal Products for Human Use (CHMP).
Industry in brief | Recordati, Genomma, Daiichi Sankyo
2 August 2019
Recordati, Genomma Lab and Daiichi Sankyo have recently released financial results.
Recordati sets out its plans for OTC business
Premium
16 May 2019
Italian pharmaceutical company Recordati is seeking further OTC acquisitions, according to chief executive officer Andrea Recordati.